Prostate
One unqualified high-risk outcomes series; no modality attribution, so it sets a benchmark rather than moving a local-therapy decision.
PROTEUS
ForHigh-risk prostate cancer; risk definition and treatment not specified in source
TL;DR5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median follow-up in a high-risk cohort.
Also covered May 31
8 details 2 trials watching
At median follow-up 60 mo: 5-yr BCR-FS 44%, 5-yr MFS 71%, 5-yr CSS 92%. No per-arm, per-subgroup, or comparator figures reported in source.
Beyond the missing design, the source names no treatment received, so the 44% biochemical failure rate cannot be read as a benchmark for any specific perioperative strategy. No N, no risk-stratification criteria, and no confidence intervals accompany the three rates.
Source gives three 5-yr rates and follow-up only. No design, N, treatment, or comparator, so no SOC read is supportable.
- Which treatment produced these outcomes
- Risk-group definition behind the 44% 5-yr BCR-FS
- Whether perioperative systemic therapy improves on this benchmark active COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer Phase 4n=144 ยท primary completion 2026-03 ยท randomised neoadj darolutamide ยฑ leuprorelin pre-RPn=20 ยท primary completion 2027-07 ยท single-arm neoadj Lu-PSMA + darolutamide, pCR pre-RP
๐ Sources ยท ๐ฆ 1 tweet
๐น Median follow-up: 60 mo
— Can Aydogdu (@CanDAydogdu) August 28, 2026
๐น 5-yr BCR-FS: 44%
๐น 5-yr MFS: 71%
๐น 5-yr CSS: 92%
Providing a real-world benchmark to contextualize perioperative treatment strategies in this high-risk population.
๐ https://t.co/NyszMg9uCA#ProstateCancer #PROTEUS #Urology